» Articles » PMID: 31296229

GENT2: an Updated Gene Expression Database for Normal and Tumor Tissues

Overview
Publisher Biomed Central
Specialty Genetics
Date 2019 Jul 13
PMID 31296229
Citations 217
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gene Expression database of Normal and Tumor tissues 2 (GENT2) is an updated version of GENT, which has provided a user-friendly search platform for gene expression patterns across different normal and tumor tissues compiled from public gene expression data sets.

Results: We refactored GENT2 with recent technologies such as Apache Lucene indexing for fast search and Google Web Toolkit (GWT) framework for a user-friendly web interface. Now, GENT2 contains more than 68,000 samples and has several new useful functions. First, GENT2 now provides gene expression across 72 different tissues compared to 57 in GENT. Second, with increasing importance of tumor subtypes, GENT2 provides an option to study the differential expression and its prognostic significance based on tumor subtypes. Third, whenever available, GENT2 provides prognostic information of a gene of interest. Fourth, GENT2 provides a meta-analysis of survival information to provide users more reliable prognostic value of a gene of interest.

Conclusions: In conclusion, with these significant improvements, GENT2 will continue to be a useful tool to a wide range of researchers. GENT2 is freely available at http://gent2.appex.kr .

Citing Articles

Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer.

Samanta T, Park J, Kaipparettu B Cancers (Basel). 2025; 17(5).

PMID: 40075691 PMC: 11898429. DOI: 10.3390/cancers17050844.


Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men.

Gong T, Jiang J, Uthayopas K, Bornman M, Gheybi K, Stricker P Nat Commun. 2025; 16(1):2400.

PMID: 40064858 PMC: 11893795. DOI: 10.1038/s41467-025-57312-9.


Deciphering the role of CNIH4 in pan-cancer landscapes and its significance in breast cancer progression.

Xu Y, Lai Z, Li C Front Genet. 2025; 16:1536620.

PMID: 40051704 PMC: 11882561. DOI: 10.3389/fgene.2025.1536620.


Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies.

Jiang Y, Xu Y, He J, Sui L, Li T, Xia N Front Pharmacol. 2025; 16:1525733.

PMID: 40046734 PMC: 11880013. DOI: 10.3389/fphar.2025.1525733.


SIRT1/DNMT3B-mediated epigenetic gene silencing in response to phytoestrogens in mammary epithelial cells.

Ma Y, Boycott C, Zhang J, Gomilar R, Yang T, Stefanska B Epigenetics. 2025; 20(1):2473770.

PMID: 40029260 PMC: 11881848. DOI: 10.1080/15592294.2025.2473770.


References
1.
Lee W, Na H, Lee S, Lim W, Kim N, Lee J . Transcriptomic analysis of mitochondrial TFAM depletion changing cell morphology and proliferation. Sci Rep. 2017; 7(1):17841. PMC: 5736646. DOI: 10.1038/s41598-017-18064-9. View

2.
Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View

3.
. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

4.
Krupp M, Itzel T, Maass T, Hildebrandt A, Galle P, Teufel A . CellLineNavigator: a workbench for cancer cell line analysis. Nucleic Acids Res. 2012; 41(Database issue):D942-8. PMC: 3531067. DOI: 10.1093/nar/gks1012. View

5.
Krupp M, Marquardt J, Sahin U, Galle P, Castle J, Teufel A . RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics. 2012; 28(8):1184-5. DOI: 10.1093/bioinformatics/bts084. View